Show/hide main menu


New efficacy results for schizophrenia anti-psychotic drugs

OCTOBER 24, 2006

Professor Robin Murray and colleagues participating in the multi-centre study CUtLASS - the Cost Utility of the Latest Antipsychotics in Severe Schizophrenia study - have published new results comparing quality of life of second (SGA) versus first-generation antispsychotic (FGA) drugs in schizophrenia in this month's Archives of General Psychiatry in the US. 

These results showed that in people with schizophrenia whose medication is changed for clinical reasons, there is no disadvantage across one year in terms of quality of life, symptoms, or associated costs of care in using FGAs rather than nonclozapine SGAs. Neither inadequate power nor patterns of drug discontinuation accounted for the result.

The CUtLASS multi-centre study group includes researchers and health professionals from the Maudsley, Cambridge University and Cambridgeshire and Peterborough Mental Health NHS Trust, Imperial College and the University of Manchester. 

Read the paper: Randomised Controlled Trial of the Effect on Quality of Life of Second Vs First-generation Antipsychotic Drugs in Schizophrenia:

Sitemap Site help Terms and conditions  Privacy policy  Accessibility  Modern slavery statement  Contact us

© 2024 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454